Eudamed Roadmap

15th July 2019

Introduction


This document presents the Eudamed High Level Roadmap as agreed between R3 and D4, with the main IT modules, milestones and the assumptions for a successful execution of the project.

OUT OF SCOPE

The High Level Roadmap is based on the current knowledge of complexity of the requirements of the last modules to be released, namely, Vigilance, Market Surveillance, and Clinical Investigations.

High Level Roadmap

The modules marked with an asterisk will be the main modules developed, in terms of functionality, of a particular release.



This roadmap does not reflect the work performed on the analysis of business requirements which was started in 2016 and which will continue throughout the project.

| OUT OF SCOPE |
|--------------|
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |

Resources

| Both Units recognize that delivering the agreed Roadmap will require additional resources in R3 from mid-2020, in particular for the delivery of releases 3 and 4. This planning brings the final delivery date to May 2022, 6 months earlier than the planning proposed to the MDCG (Medical Device Coordination Group) recently |
|---|
| |
| |
| |
| OUT OF SCOPE |
| |
| |
| |
| OUT OF SCOPE |
| |
| |
| |
| |